Docosahexaenoic Acid Supplementation And Cognitive Decline In Alzheimer Disease: A Randomized Trial
Effect | None |
Trial Design | Double blind |
Trial Length | 6+ Months |
Number of Subjects | 295 |
Sex | Both Genders |
Age Range | 65+ |
Body Types | Overweight, Average |
2,000mg DHA from algae for 18 months failed to significantly delay symptoms associated with Alzheimer's disease or reduce the rate of cognitive decline as assessed by CDR and ADAS-cog rating scales. Similarly, the rate of brain atrophy was not affected.